TY - JOUR
T1 - Harnessing immune responses in the tumor microenvironment
T2 - All signals needed
AU - Le, Dung T.
AU - Jaffee, Elizabeth M.
PY - 2013/11/15
Y1 - 2013/11/15
N2 - An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.
AB - An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=84888112421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888112421&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-2424
DO - 10.1158/1078-0432.CCR-13-2424
M3 - Article
C2 - 24097857
AN - SCOPUS:84888112421
SN - 1078-0432
VL - 19
SP - 6061
EP - 6063
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 22
ER -